Skip to main content
European Commission logo print header

Therapeutic strategies using vegf substitutes and gene therapies to maintain the integrity of the arterial wall

Objective

The Partners have proposed a new hypothesis whereby vascular endothelial growth factor (VEGF) is arterioprotective in intimae hyperplasic and arteriosclerosis. That cell signalling of the VEGF family, which underlines the production of NO and PGI_2, is the basis of the arterioprotective effect will be elucidated. Peptides will be synthesised and used as probes and as substitutes for the VEGF receptors in functional studies. The peptides will be the basis of future cytoprotective medicines. Rabbit and mice models of VEGF protective functions will be used. Novel VEGF- and PIGF-induced genes will be discovered leading to novel therapies. Transgenic mouse models lacking or expressing mutant forms of the VEGF family of genes will be used to evaluate the vasculoprotective role in intimae hyperplasic and arteriosclerosis. This project will elucidate the mechanisms involved in arterioprotection by VEGF and produce novel arterioprotective therapeutics.

Call for proposal

Data not available

Coordinator

Birkbeck College, University of London
EU contribution
No data
Address
Malet Street, Bloomsbury
WC1E 7HX London
United Kingdom

See on map

Total cost
No data

Participants (3)